Maternal FAdV-11 antibodies protect neonatal chicks in vaccine study
Bottom line
Version 1
A new study in Veterinary Sciences reports that maternal antibodies generated by vaccinating breeder hens with a fiber-based subunit vaccine fully protected newly hatched chicks against experimental challenge with fowl adenovirus serotype 11, an important cause of inclusion body hepatitis (IBH). In the study, the investigators used a hypervirulent FAdV-11 strain isolated from an IBH outbreak in Hubei Province, China, and found it caused 90% mortality in 1-day-old specific-pathogen-free chicks. By contrast, chicks that received maternally derived antibodies from vaccinated hens were completely protected in the neonatal challenge model. The work adds to a growing body of evidence that fiber proteins are among the most promising antigens in FAdV vaccine development, especially for breeder-focused strategies aimed at protecting chicks during their most vulnerable early-life window. (merckvetmanual.com)
Why it matters: For veterinary professionals working with poultry systems, the study reinforces a practical disease-control principle: protection against IBH may depend as much on breeder immunity and maternal antibody transfer as on chick-level interventions. That matters because FAdV-associated disease is often concentrated in young broilers, vertical transmission is part of the epidemiology, and there is still no universally available commercial vaccine solution across markets and serotypes. A subunit platform could also be attractive from a safety and manufacturing standpoint versus live approaches, although field performance, duration of immunity, serotype breadth, and commercial-scale economics still need to be proven. (merckvetmanual.com)
What to watch: The next question is whether this serotype-specific maternal protection can be reproduced in commercial breeder flocks, and whether developers can broaden coverage across FAdV-2, -8a, -8b, and -11, the serotypes most tied to IBH. (sciencedirect.com)
Key facts
- Study journal
- Veterinary Sciences
- Vaccine type
- Fiber-based subunit vaccine
- Target
- Fowl adenovirus serotype 11 (FAdV-11)
- Challenge strain
- FAdV-11/HB2022/1
- Challenge severity
- 90% mortality in 1-day-old SPF chicks
- Main finding
- Maternal antibody transfer provided complete protection in neonatal chickens
- Disease
- Inclusion body hepatitis (IBH)
- Context
- FAdV-2, -11, -8a, and -8b are among the serotypes most often implicated in IBH
Version 2
A new poultry vaccine study suggests maternal immunity may be a powerful tool against one of the industry’s persistent early-life viral threats. Writing in Veterinary Sciences, researchers reported that maternal antibody transfer induced by a fiber-based subunit vaccine provided complete protection against fowl adenovirus serotype 11 in neonatal chickens under experimental challenge conditions. The challenge strain, FAdV-11/HB2022/1, was described as hypervirulent and caused 90% mortality in 1-day-old SPF chicks, underscoring the severity of disease pressure the vaccine strategy was designed to address. (merckvetmanual.com)
The backdrop is a broader resurgence of concern around fowl adenoviruses, which are associated with IBH, hepatitis-hydropericardium syndrome, and other production-limiting diseases in poultry. Reviews and reference sources describe IBH as a globally important disease of young broilers, with FAdV-2, -11, -8a, and -8b among the serotypes most often implicated. Researchers have also emphasized that prevention strategies need to account for both direct infection in chicks and vertical dynamics, including transmission of virus and protective antibodies from breeders to progeny. (merckvetmanual.com)
That context helps explain why maternal immunity is drawing attention again. Earlier work has already shown that breeder vaccination can protect offspring against IBH-causing adenoviruses. In one 2017 study, maternally derived antibodies from hens vaccinated with FAdV-8b subunit candidates protected progeny against clinical IBH, while other breeder-vaccination studies showed broad protection in chicks after parental immunization with live or bivalent FAdV vaccines. The new FAdV-11 paper builds on that concept, but focuses specifically on a fiber-based subunit approach targeting a serotype increasingly associated with IBH outbreaks. (pubmed.ncbi.nlm.nih.gov)
Fiber antigens have become a recurring theme in FAdV vaccine R&D because they can drive strong neutralizing antibody responses. Prior studies have shown that fiber-based subunit vaccines can provide complete homologous protection against FAdV-4, and a 2020 study in Veterinary Research found that a fiber-based IBH vaccine provided type-specific protection guided largely by humoral immunity. That type specificity is important: it helps explain both the promise and the limitation of the current result. Strong maternal protection against FAdV-11 is encouraging, but it does not automatically solve the multiserotype reality seen in commercial poultry. (pubmed.ncbi.nlm.nih.gov)
Industry and academic reviews are increasingly pointing in the same direction. A recent vaccine review concluded that fiber proteins remain among the most successful subunit antigens for FAdV, while also noting that epidemiology and maternal antibody transfer substantially shape protection strategies. More recent work has tried to address the serotype problem directly, including multivalent inactivated formulations and chimeric fiber constructs designed to induce cross-neutralizing antibodies against both FAdV-4 and FAdV-11. Those efforts suggest the field is moving beyond proof of concept toward broader, more field-ready vaccine designs. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For poultry veterinarians, the study is less about a single experimental result and more about where control programs may be headed. If breeder immunization can reliably generate protective maternal antibody levels against virulent FAdV-11, that could strengthen prevention during the narrow neonatal window when chicks are most vulnerable and before active immunity is established. It also aligns with commercial realities: vaccinating breeders is often more feasible than protecting day-old chicks individually. At the same time, veterinary decision-makers will need to weigh serotype distribution in their region, possible co-circulation of multiple FAdV types, the durability of maternal antibodies, and whether a candidate can perform outside SPF challenge models. In the US, extension guidance has noted that FAdV is widespread and that no commercial vaccine had been approved as of the referenced publication, making regional regulatory and market context especially relevant. (ask.ifas.ufl.edu)
What to watch: The next milestones are likely commercial-breeder validation, cross-protection data against additional IBH serotypes, and any movement toward multivalent or chimeric products that can better match field epidemiology. If those data hold up, fiber-based maternal immunization could become a more serious contender in poultry adenovirus prevention programs. (mdpi.com)